Adocia announced that it was notified in a letter dated January 26 from Eli Lilly and Company its decision to terminate the December 2014 Collaboration Research and License Agreement for the development of Adocia's ultra-rapid insulin, known as BioChaperone Lispro, for treatment in people with type 1 and type 2 diabetes. As a consequence of such decision and according to the terms of this agreement, the rights that Adocia has licensed to Lilly will revert to Adocia at no cost.